Mental Health & Therapy
Biometric feedback digital therapeutics for anxiety, PTSD, and depression with real-time adaptive interventions.
Why This Market Matters
Mental health is in crisis. Therapist shortages, stigma, cost barriers—the traditional model cannot scale to meet demand.
Digital therapeutics offer hope, but current solutions are static. They deliver the same content regardless of whether it's working.
Our technology enables therapy that responds in real-time to whether the patient is actually improving—adapting intensity, pacing, and approach moment by moment.
Clinical Applications
PTSD Treatment
Exposure therapy that adapts intensity to physiological tolerance. Prevents re-traumatization while ensuring therapeutic progress.
Key: Anxiety markers, stress response, dissociation indicators
Anxiety & Panic
Calming content generated in response to actual anxiety markers. Intervention when it matters, not on a schedule.
Key: HRV, skin conductance, respiratory rate
Addiction Recovery
Cue exposure therapy with controlled trigger exposure. Builds tolerance without triggering relapse.
Key: Craving indicators, stress response, heart rate
Depression
Mood-responsive content that adapts to engagement and affect. Maintains motivation during difficult periods.
Key: Engagement metrics, facial expression, activity level
ADHD
Engagement-optimized learning and therapy that maintains attention based on real-time focus markers.
Key: EEG attention metrics, eye tracking, fidget detection
Autism Spectrum
Sensory-adapted content that responds to stress and overwhelm indicators. Prevents meltdowns, supports regulation.
Key: Sensory load indicators, stress markers, engagement
Insomnia
Sleep induction content that guides users based on brainwave state. Adapts as you drift off.
Key: EEG sleep stages, heart rate, respiratory pattern
Phobias
Gradual exposure with dynamically generated scenarios. Progress at exactly the rate the patient can handle.
Key: Fear response, avoidance behavior, tolerance building
Eating Disorders
Therapeutic content with biometric-responsive interventions during challenging moments.
Key: Anxiety markers, meal-time stress, body image response
FDA Digital Therapeutics Pathway
FDA-cleared digital therapeutics can access reimbursement pathways and payer coverage through established clinical and billing frameworks.
Our technology enables a new category of adaptive digital therapeutics that demonstrate superior outcomes through real-time personalization.
The regulatory pathway exists. The clinical evidence requirements are clear. The market is waiting.
Commercialization Signals
Target Partners
Digital Therapeutics
- Pear Therapeutics
- Akili Interactive
- Happify Health
- Limbix
- Big Health
Telehealth Platforms
- Teladoc
- BetterHelp
- Talkspace
- Lyra Health
- Spring Health
Healthcare Systems
- HCA Healthcare
- Kaiser Permanente
- Cleveland Clinic
- Mayo Clinic
Government/Military
- VA (Veterans Affairs)
- DoD
- NIH/NIMH
- DARPA
The Clinical Advantage
Current digital therapeutics deliver static content. A patient doing exposure therapy gets the same intensity regardless of whether they're coping or spiraling.
With Tezit's technology, therapeutic content responds in real-time to the patient's actual physiological state. The system knows when to push forward and when to ease back.
This isn't just a feature—it's a fundamental shift in how digital therapeutics work. And it's protected by our patent application.
Technical Deep Dive
The patent-pending loop ingests clinical-grade biometrics (HRV/ECG, EDA, respiration, pupil dilation, eye-tracking, facial affect, EEG where available) and computes a deviation to an intended therapeutic state (e.g., controlled exposure arousal window, relaxation band, focus band). That deviation conditions a generative model to synthesize new therapeutic stimuli—scenes, scripts, exposure intensity, auditory guidance—explicitly disallowing reuse of preauthored branches per the negative limitation.
Adaptation knobs include exposure dose titration for PTSD/phobia, respiratory pacing for panic, mood-congruent or mood-lifting content for depression, and sensory load management for autism. Latency targets (<100 ms) keep interventions temporally coupled to physiological signals. For insomnia, EEG stage markers and HRV drive hypnagogic audio/visual synthesis that eases users across sleep onset without abrupt transitions.
Multi-user weighting supports therapist-in-the-loop or group sessions, allowing clinician annotations to modulate weights or override when needed. User records persist biometric-response trajectories, content parameters, and outcomes to power personalization while complying with HIPAA/GDPR/biometric privacy constraints. This evidence base can support FDA De Novo/510(k) submissions by demonstrating superior, adaptive outcomes versus static digital therapeutics.
Interested in Mental Health & Therapy?
Let's discuss how Nourova's patent-pending technology can transform your mental health & therapy applications.
Discuss Licensing